

**APPENDIX A: CLEAN COPY OF PENDING CLAIMS (UNOFFICIAL)**

1. A method of treating hypertrophy in a subject comprising the step of inhibiting the function of NF-AT3 in a cardiomyocyte, wherein inhibition of NF-AT3 function inhibits hypertrophic gene expression, thereby treating hypertrophy.
4. The method of claim 1, wherein inhibiting the function of NF-AT3 comprises contacting said cardiomyocyte with an agent that binds to and inactivates NF-AT3.
9. The method of claim 4, wherein the agent that binds to and inactivates NF-AT3 is an antibody preparation or a small molecule inhibitor.